Category Archives: Embryonic Stem Cells


Stem Cell Therapy Market: Business Opportunities, Current Trends and Industry Analysis by 2018 2028 – Instant Tech News

Stem Cell Therapy Market Insights 2019, is a professional and in-depth study on the current state of the global Stem Cell Therapy industry with a focus on the Global market. The report provides key statistics on the market status of the Stem Cell Therapy manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the report provides an in-depth insight of 2019-2025 global Stem Cell Therapy market covering all important parameters.

Request Sample Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1787&source=atm

The key points of the Stem Cell Therapy Market report:

The report provides a basic overview of the Stem Cell Therapy industry including its definition, applications and manufacturing technology.

The report explores the international and Chinese major industry players in detail. In this part, the report presents the company profile, product specifications, capacity, production value, and 2019-2025 market shares for each company.

Through the statistical analysis, the report depicts the global total market of Stem Cell Therapy industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export.

The total market is further divided by company, by country, and by application/type for the competitive landscape analysis.

The report then estimates 2019-2025 market development trends of Stem Cell Therapy industry. Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out.

The report makes some important proposals for a new project of Stem Cell Therapy Industry before evaluating its feasibility.

Request For Discount On This Report @ https://www.tmrresearch.com/sample/sample?flag=D&rep_id=1787&source=atm

There are 3 key segments covered in this report: competitor segment, product type segment, end use/application segment.

For competitor segment, the report includes global key players of Stem Cell Therapy are included:

Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

Customize This Report @ https://www.tmrresearch.com/sample/sample?flag=CR&rep_id=1787&source=atm

Reasons to Purchase this Report:

* Estimates 2019-2025 Stem Cell Therapy market development trends with the recent trends and SWOT analysis

* Market dynamics scenario, along with growth opportunities of the market in the years to come

* Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects

* Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.

* Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years

* Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

Read more from the original source:
Stem Cell Therapy Market: Business Opportunities, Current Trends and Industry Analysis by 2018 2028 - Instant Tech News

Anatomy of a grant: Ashley Kramer’s yearlong journey to finding her doctoral thesis – The South End

He asked her for a list of dream projects she would love to investigate. What followed was a year of challenges, stresses and the ultimate reward guided intellectual freedom toward scientific discovery.

Ashley Kramer, a student at the Wayne State University School of Medicine, is enrolled in the schools M.D.-Ph.D. program, an eight-year commitment broken down into three parts the first two years of medical school, four years of graduate school, then the final two years of medical school. Like all M.D./Ph.D. students at the medical school, Kramer had to complete research rotations with faculty she thought would make good dissertation advisors.

Because I have always loved stem cell biology and had experience working with zebrafish in the past, I decided to do an eight-week rotation in Dr. Thummels lab between my medical year one and medical year two, and made the decision that this was absolutely the perfect lab for me, she said.

Ryan Thummel, Ph.D., is an associate professor of Ophthalmology, Visual and Anatomical Sciences. His lab focuses on retinal development and regeneration in zebrafish, an attractive model to study neurodegenerative diseases because of its ability to regenerate neuronal tissues. Zebrafish fully regenerate their retinas in just a matter of weeks, an ability mammals lack.

Zebrafish and mammals both have a cell called Mller glia that supports retinal neurons. In zebrafish, however, these cells convert to stem cells and are responsible for retinal regeneration.

At the end of the rotation, Dr. Thummel floated the crazy idea of starting to work on this grant, a 70-plus page monster undertaking, during my M2 year, and I immediately jumped at the opportunity. I was excited at the idea of having a four-year research project completely planned out by the time I started my Ph.D. after M2 so I could hit the ground running after the dreaded STEP 1, Kramer said.

I came to him two days later with a nine-page document of project ideas. We sat down for three hours discussing projects and came up with a top-two list of cohesive projects for me to move forward with as a grant and thesis, she said. From there, it was a nearly yearlong process of writing, meeting, revising and repeating for each of the many sections of the grant.

The effort was worth it. Kramer secured a five-year, $294,102 grant from the National Eye Institute of the National Institutes of Health last year to study the molecular mechanisms of retinal regeneration in zebrafish, an organism that exhibits a remarkable capacity for regeneration.

"Ashley is a dedicated young scientist and worked very hard on this grant application," Dr. Thummel said.

The grant is one of the NIHs Ruth L. Kirschstein National Research Service awards, also known as an F30. The project, Elucidating the role of DNA methyltransferases in epigenetic regulation of retinal regeneration in the zebrafish, started last month. She is the principal investigator.

This was an incredibly challenging experience that allowed me to grow immensely as a scientist. Grant writing, planning effective and novel longitudinal scientific investigations, and time management will all be critical skills for me moving forward in my career as a physician scientist, she said. I cannot thank Dr. Thummel and my past advisors enough for all of their mentoring and support in the last ten years who have gotten me to where I am today, and I am looking forward to the rest of my training here at Wayne State and beyond.

Kramer earned her bachelors degree in Genetics, Cell Biology and Development from the University of Minnesota in 2014. Her love of research and stem cell biology started when she was an undergraduate research assistant there.

Nearly a decade later, she is studying how epigenetic marks are added to, and removed from, genes in zebrafish retinal stem cells during the process of retinal regeneration. The role of epigenetics in the body is akin to traffic signs on the road.

If roads had no traffic lights, stop signs or barricades, it would be complete chaos. The same is true for your cells. If you used every single gene encoded in your DNA 100% of the time, your cells would be chaos. Epigenetics is what is responsible for telling your skin cell to be a skin cell and your liver cell to be a liver cell, while they both have the exact same underlying DNA sequence, Kramer said. There are various different epigenetic marks that decorate the DNA without actually changing the sequence. These marks come in many forms and can act to either start, stop or change the amount that a particular gene is used, similar to how a green light, road block or stop sign direct traffic rules.

The process is critical for normal embryonic development and everyday cell processes.

If we can gain a deeper understanding of how species like the zebrafish are able to regenerate tissues when mammals cannot, despite having the same cell types, we may be able to start working to translate those mechanisms to mammals, she said. It is possible that certain regeneration pathways have been epigenetically silenced through evolution and we may be able to use modern advances in gene therapy techniques to unlock regenerative capacity in mammals.

Follow this link:
Anatomy of a grant: Ashley Kramer's yearlong journey to finding her doctoral thesis - The South End

The Challenge of Bioethics to Decision-Making in the UK – Westminster Abbey

Past Institute lectures

A lecture for the Von Hugel Institute series Ethics in Public Life, 5th February 2015, given by Claire Foster-Gilbert, Director, Westminster Abbey Institute.

The context of the series of lectures of which this is one is ethics in public life, and I would like to start by taking some time to describe the creation and operation of Westminster Abbey Institute, and use it as a prism for our consideration of bioethics and decision making in the UK. I want to say a little bit about the sacred-secular divide which I do not see. Then the two thorny examples I will use in bioethics, when I come to them, will be embryology and assisted dying.

Westminster Abbey Institute was launched in November 2013 to revitalize moral and spiritual values in public life, working with the public service institutions around Parliament Square, and drawing on its Benedictine resources of spirituality and scholarship.

Westminster Abbey sits on the south side of Parliament Square, with the Judiciary in the form of the Supreme Court on the west side, the Executive in the form of Whitehall on the north side, and the Legislature in the form of the Houses of Parliament on the east side. The Institute is the Abbeys answer to the question: what is it bringing to public service and how can it support those in public office?

We knew, when we started, what we were not: a think tank, part of the commentariat, a campaigning organisation, nor a fawning courtier. Nor were we apologists for religion in the public square. The Abbey is already more integrated than that. There is no sense of a sacred-secular divide, and as I go about my work as Director I feel none between my work and that of the public service institutions around the Square. The similarity is that we are identifying at the heart of the Parliament Square endeavour a sincere wish to support the good, to serve society, to make things better in the world. And in that sincere wish I see spirit moving, hearts opening, minds analysing, bodies acting, as a holistic, responsive flow to the call of public service.

I am not naive: the motivation to serve the public and the vocation to public service are not pure. In amongst the good wheat of service are the tares of motives such as selfish ambition, personal gain, fame, and the needy weakness of human nature to be recognised and rewarded. I see those other motives, but I know them for my own also, so am in no position the Abbey Institute is in no position, lets be clear to judge or condemn them. Like the parable, we leave that till the harvest. And meanwhile, by supporting the good, believing in the motives that are for service, recognising and applauding the rightness in the work around the Square, the murky tares, if I may torture the analogy beyond its capability, melt away. We hope.

I see a wholeness, then, responding to a call to serve. The deeper the response the more effective and lasting it will be and here is a place where our religion makes a specific contribution. The further back into God it reaches, the more effective and lasting and good the call to public service will be. I call it God. Spirit, depth, the swirling deep movement of creativity, the meditation of the soul, the rest before action. The further the archer draws back the bow, the further and truer the arrow will fly. It has been notable just how much of a longing for depth has shown itself in the people and institutions around the Square in the short time the Institute has been operating.

Our method is first to offer a Benedictine context. That is, we offer conversation that locates itself in stability, community and the conversion of manners. We will sit down with a group of, say, senior Civil Servants, or those tasked with offering professional development to MPs, or a group of Peers, and together we will devise a seminar for their department or group which will look at the good that the department or group is trying to do. What is significant and distinctive is that the psychological and philosophical location of the conversation is deep. That depth is also physically expressed by the Jerusalem Chamber where King Henry IV died and V became King, and the King James Version of the Bible was finalised, and so forth, where the seminars happen. Part of the Abbots and then the Deans lodging, a space where spiritual and worldly do not separate.

I was set a great example of how to do depth by Rowan Williams when he was the interlocutor for a series of four public conversations at St Pauls Cathedral, taking in turn global economy, ecology, governance and health, and asking the experts in those fields questions which immediately drew them into a consideration of the philosophical and even theological underlying currents of the subjects. The bishops did a similar thing with genetics experts when they spent a day learning about the subject. They were really good questions, and ones that practitioners, officials, public servants often dont have time to ask, but they are the most important questions because they lead us into our spiritual humanity.

A really lovely example emerged yesterday when we were sitting around the table in the Permanent Secretarys office of a Government Department, discussing a forthcoming seminar for the Department. One of the Civil Servants spoke about how too often officials in the Department will apply formulaic approaches, such as the benefit-cost ratio, in a way that masks or even undermines vital human qualities such as empathy and humility, and we will look at this in the seminar. Importantly, the words and the disposition came from the Civil Servant, not from the Abbey Institute. We are not functioning on the Square to tell others what the Good is. It emerges in the encounter.

So the conversation is located in a Benedictine place (in a way, for a short while, that Permanent Secretarys office became a Benedictine space). First, it is stable, it is safe here, and here is not going to go away, its an historical place where we can feel our own passing, gain a perspective on our place in history. Second, it is a place of community, which means that we are gathered in goodwill together, seeking the good together, united in our efforts and made companions in our purpose, not by any means agreeing with each other but feeling safe with each other. As a community of goodwill we feel it is safe to get things wrong, to take time to form conscience, to work things out. And of course we operate to the Chatham House rule. Third, we are about the conversion of manners. We expect transformation to take place though we dont necessarily know what it will be. Broadly, though, borrowing from Philip Shepherd, we will be looking for moves:

And I dont mind admitting that this transformation is probably only realised after the talking is over and everyone has gone to evensong and then wandered around the Abbey in the semidark and silence of the close of the day and had a glass of wine back in the Jerusalem Chamber!

In agreeing that we are a community of goodwill seeking to articulate the good I have offered an analogy from sailing that works well. A Government Department can be imagined as a sailing boat. At the helm stands the Permanent Secretary, who, like all good helmsmen, seeks never to steer the boat more than five degrees either side of the compass direction upon which the boat is set. Civil Servants in the Department form the crew, from the navigator who must know the course and ensure the helmsman anticipates obstacles, to the scrubber of decks who ensures no one slips up. All play their part in ensuring the boat remains shipshape and able to withstand the waves and the winds in travelling its appointed course.

The waves are the events of the nation and the world. They may be relatively calm or they may rise into steep and stormy mountains of water, threatening the stability of the boat.

The winds are public opinion, which can fill the sails of the boat and send it scudding on its chosen course. They can gust and buffet, interrupting the boats smooth journey. Or they can blow adversely, threatening to push the boat off course altogether.

Hence, the helmsman cannot simply hold the tiller fixedly. He or she must constantly respond and adjust to the wind and the waves, aiming to keep within five degrees either side of the compass direction or risk increasingly over-compensatory swings away from the course of travel.

The compass point towards which the boat is sailing is The Good. As such, it is not a destination; the journey is the thing, the direction of travel the concern, not the arrival.

By whom is The Good defined? It is true that the Government Minister is granted that responsibility and privilege by virtue of having been elected by universal franchise. But in defining The Good, Ministers have to have their Partys support. And of course the strength of the prevailing wind, public opinion, may be such as to determine a change of compass direction altogether. For the politician, public opinion will set parameters on what he or she can achieve. The great political leader will have a vision of the Good that transcends narrowminded concerns but retains Party support, and respects the parameters set by the prevailing wind of public opinion. The visionary and skilled politician will learn, quite possibly from his or her Civil Servants, about the art of tacking.

Because of course it is the helmsman and the crew who execute the tack, and any other sailing manoeuvres required. The Civil Service crew, having gathered the evidence sniffed the wind, watched the waves will need to be able to tell Ministers when their proposed direction of travel will not work: when, whatever the Ministers might want to think, their proposed direction is possibly not towards The Good. Thus the Good is sought by all.

And in passing, if one imagines Whitehall as a fleet of boats, those, too, will need to be taken into account by the helmsman. But and it is a wonderful sight sailing boats, journeying as a fleet in the same direction across the waves, subject to the same wind, stay uniform distances apart.

Having established a common concern with identifying the Good, seated in our Benedictine space, we then spend time as moral philosophers, looking at the specifics of the policy drivers for a given Government Department. Our analysis is rigorous, using the method I developed in the Centre of Medical Law and Ethics at Kings College, London, under Ian Kennedy, in the 1990s.

We use the three broad approaches that moral philosophers have taken over the centuries as they have sought to determine what is good. These we have called goal-based, duty-based and right-based, following Dworkinii, Botrosiii and Fosteriv. Very briefly and broadly, a goal-based thinker will see the good of an action in its consequences rather than in the content of the action itself; a duty-based thinker will look at the action and judge it according to preexisting moral rules; and a right-based thinker will judge the action according to the views of those most affected by it. The goal-based approach is valid insofar as it is the case that we rarely act without some end in view and it is right to consider whether that end is a good one. The goal-based approach is limited in that even very desirable goals should not justify actions which in themselves are intrinsically nasty. The ends are important moral considerations but they dont justify the means. Morality is not a mathematical exercise. The duty-based approach is valid in that it makes us think hard about what we are doing rather than merely why we are doing it, recalibrating the needle of our moral compass, making us morally sensitive rather than mathematically certain. The duty-based approach is limited because it can blind us to important consequences (Kant would have us truthfully respond to a murderer seeking her prey); and it is limited because it can make us arrogant: concerned only with our own place in heaven earned by doing the right thing, regardless of its effect or the views of others (the poor soul who will be murdered because Kant refused to tell a lie, or the patient who wants his life support switched off and we refuse to take a life). The right-based approach is valid because it requires us to listen to others, it makes us community-minded instead of purist. It is limited because on its own it would make someones request, for example, to take their life, right with no other consideration except that it is their wish.

All three approaches are needed. They conflict, they make us think, they require sensitive responses, honest appraisal, self-awareness because we will temperamentally favour one approach over the others, but taken together they form a three-legged stool that stands firm, if the legs are all of the same length, even on rocky ground.

And then comes the real challenge of bioethics. The Department of Health wants us all to live better for longer. But when does life begin and when does it end? I want in this third and final part of my lecture to explore the contemporary challenge of these questions by looking at two issues embryology and assisted dying that have been working their way around Parliament Square, with cases in the Supreme Court, policy development in Whitehall, and legislation or attempts at legislation in the Houses of Parliament.

Human fertilisation and embryology are scientifically complex and they are also, at every stage, morally sensitive. The challenge to Government and Parliament has been whether and how to draw these extraordinary scientific developments within a regulatory framework in a way that respects the science and does not ride roughshod over the sensitive moral questions, or ban the research and practice altogether. Having chosen the former course of action, what principles needed to underlie the regulatory framework?

Let us take a step back in time and thought. Let us bring the issue into our safe Benedictine space. Here we are allowed to think out aloud. We do not have to have a pre-determined position, but if we do, we wont be shouted down or assumed to be on the side of the devil.None need feel defensive. In this Benedictine space we are seeking the Good, aware that many have tried before us and God willing there will be many afterwards, all calibrating their moral compass and seeking to steer the boat no more than five degrees either side of the compass point, but having to allow, because of the wind of public opinion and the waves of ever changing events, that much leeway either side. We know we will not find perfect answers.

And now for the three-legged framework. From a goal-based perspective, we ask what embryology is for, and why it matters. Embryology is important as a cure for infertility, as a therapeutic response to currently incurable diseases using cell transplantation and, very recently proposed, eliminating mitochondrial disease altogether. Its goals, then, are for life: new life, and curing diseased life. No one, really, could argue with the goals of embryology. We would want the research and practice to be done excellently, so as to ensure these good goals were reached, but from a goal-based perspective, taken on its own, there can be no quarrel with it.

From a duty-based perspective, what does embryology involve? Here the moral questions start to bite. The first question must be about the status of the embryo itself. Because if the embryo has the same status as a human life, no matter how wonderful the goals are, no one would countenance destroying a human life to reach them, and embryology (which always involves destroying embryos) would fall at this moral fence.

The reasons you might regard the embryo as a human life are as follows: the embryo is formed from the fertilisation of an egg by a sperm forming a unique genome no one (if it is a person) was ever like it before, and no one will be ever again. We, each of us diverse people, were all embryos once. If we are to choose a point when life begins, the formation of the fertilised egg is certainly a definite stage one could choose.

The reasons you might not regard the embryo as human life are: the place of fertilisation is not the womb or the field in which the embryo is implanted, but at the base of the fallopian tubes. The embryo still has a journey to make to reach the womb and implant. (Some Shia teaching on this argues that life cannot be said to have begun until the seed, egg and field are all in place, ie at implantation.) During that journey, in the normal course of events, 70% of embryos do not reach the womb. It is during that journey that the all-important stem cells start to proliferate, hence the interest in the early, pre-implanted embryo, not the fetus in the womb. During that journey, the embryo may divide and become more than one fetus, hence genetically identical twins. These reasons may persuade you that it would be acceptable to see the early embryo not as human life but as potential life, and that its use therapeutically is acceptable. You may feel the goal-based tug: the status of the early embryo is in question, and the use of them therapeutically is so full of promise Should the duty-based consideration, that the embryo has independent moral status like that of a human being, give way?

What is important to recognise is that we do not say that the embryo has no status. The legislation has recognised its moral importance by regulating its use. But the law has accepted that the embryo is not the same as a human life.

From a right-based perspective, you cannot really make a judgement. The embryo cannot speak for itself. Is it fanciful to conduct a thought-and-feeling experiment predicated on the fact that we were all embryos once. Would we be happy to have been destroyed even before reaching the womb, to save another life or lives, or to create a new life? ??

The other right-based question relates to those who might benefit from stem cell or mitochondrial therapy: if they think of the embryo as having human status they may not want to benefit from such treatment. Healthcare practitioners may seek to be conscientious objectors.

The challenge to UK decision-making of embryology has been profound and I think, myself, that we have not done badly at it. Prior to this last development on mitochondrial DNA, the debates have been long and thoughtful, no speedy legislation was drawn up (except to prevent cloning), and the regulation is careful. In the UK, embryo research can take place but it is all regulated. (In the US, embryo research may not take place if it is federally funded; if you can pay for it yourself, you can do what you like!)

However, courts continue to be referred to as no legislation could possibly anticipate the science. It has turned out that the most fruitful source of embryonic stem cells has not come from embryos but from de-differentiated adult cells. Since however these de-differentiated cells, if placed in a womb, could theoretically grow into a clone of the person whose cell it was, this has had to be specifically outlawed and, much more recently, and potentially worryingly, a court has ruled that: The mere fact that a parthenogenetically activated human ovum commences a process of development is not sufficient for it to be regarded as a human embryo. This judgement opens the way to patenting the process of creating stem cells. It is potentially worrying since it arguably robs the embryo of its moral status. However, what is the status of a de-differentiated cell, which could originate from any one of the bodies in this room just by scraping our skin?

Is the very recent decision of the Commons to allow the process that removes diseased mitochondrial DNA from the offspring of mothers with the disease a case of slipping down a slippery slope into unethical waters? Is it the first step towards eugenics, since it eliminates the disease from the germ line permanently? Or is it an intelligent use of skills and techniques we have developed through carefully regulated embryo research, that will allow the cure of a vile disease?

Assisted dying, unlike embryo research, has not been made legal and given a set of regulations by which to abide. Despite its repeated return to Parliament and the apparent public support for a change in the law, none has happened, as yet. In practice, cases have been decided by the Courts and the number of cases coming to the Courts is only increasing. It is something of a sore point for the judges: they cannot turn cases away. All the time, as they see it, Parliament refuses to take the bull by the horn and create legislation, they are obliged to give judgements on a case by case basis that creepingly changes the law, and it is changed by lawyers not by democratically elected representatives of the public debating in public.

Before reflecting on the challenge to law and policy-makers that assisted dying has posed, let us once again step back into our Benedictine space, and we should pause here for a moment and recollect that the primary quality of that space is listening

And now conduct our analysis. Assisted dying is the act of making available to a person, who has expressly and competently asked for it, the means to take his or her life by their own hand.

From a goal-based perspective, one goal of assisted dying is to alleviate suffering. Another is torespect the autonomy of individuals. Another may be put more boldly: to end life deliberately.

From a duty-based perspective, principles of the sanctity of life and of respecting autonomy both raise their concerns, and conflict. How are they resolved?

From a right-based perspective, the principle of respect for autonomy trumps any duty of other individuals to save, sustain or end life. It is, simply, up to the individual. When polls are taken on the subject of assisted dying and euthanasia the vast majority of responses are in favour of it, on the grounds, though, that it is my life to do with as I please and who is any doctor to prevent me. But a law that permitted a solely right-based approach that the request should be granted simply because it had been made would be impossible to apply. It would be impossible to know if the person had actually asked for death, because they would be dead. Additional safeguards have to be included in any legislation, and these require that certain relevant professionals are satisfied that the conditions allowing assisted dying are met. This is not, then, a purely rights-based activity any more. Similar difficulties arise in seeking abortion - it is not, in the legislations, simply up to the mother whether or not the abortion takes place. She has to satisfy two doctors that she fulfils the criteria set by the law. The fact that doctors will very often sign the forms without questioning the mother, because they take a right-based approach in profoundly believing in her right to choose, is symptomatic of the challenge of lawmaking in areas of bioethics.

If the dying in question is assisted only, ie the person has to take the lethal substance themselves, this right-based problem is allayed. That is to say, we may be fairly sure that if the pink drink given by organisations such as Dignitas is drunk without assistance once it is put in the hands of the one seeking assisted dying, then he or she most definitely did want to die.

We cannot know what passes in their hearts however, and Mary Warnock has been worryingly at ease with the idea that it would be perfectly all right to seek euthanasia on the grounds that one felt a burden to ones family and friends. The wishes and needs of the community of that individual: family, loved ones, society are all included in the right-based approach, and what of these? Chaplains ministering to those receiving euthanasia in Holland speak of the devastation of families, resonant of the desolation of the families of suicides.

The most recent case that came to the Supreme Court was that of Nicklinson, Lamb and the Director of Public Prosecutionv. Nicklinson and Lamb were both almost entirely paralysed; Nicklinson from a stroke which left him able to blink only and Lamb from an accident that meant he could only move his right hand. Hence neither would be able to take the pink drink unaided, so both wished to be assisted to die without fear of prosecution of those who helped. The Director of Public Prosecution sought the freedom to decide on the matter of assisting suicide on a case by case basis.

In the Supreme Court, all the Law Lords agreed that Article 8 of the Human Rights Act (which is the right to a private life, to be overridden only in the case of threats to public safety or criminal acts) is relevant to the issue of assisting someone to die if it is their express wish. That is to say, domestic rulings can be made by way of interpretation of the Article in relation to assisted suicide. But while some Law Lords believed that it was a right for a person to be assisted to die if it was their express wish, according to Article 8, others did not. It was recognised that there was a fundamental incompatibility between the sanctity of life and autonomy. Several Law Lords argued strongly that the debate should be held in Parliament as the representative body of society, not judged upon by appointed Justices. And indeed there is yet another bill to allow assisted dying making its way through the House of Lords now. It has reached the stage where the Lords are working through more than 100 amendments, some of which are clearly intended to wreck the bill, whilst others provide clarification and strengthening of safeguards. And arguably the intellectual purity of the moral reasoning of the judges is a better place to turn to than the mess of Parliamentary debate. What a strange way for law on such a sensitive and controversial issue as the management of the dying process to be written: by the tug of war of differing factions and the compromise that will inevitably be reached if the bill is to succeed.

And yet, how are we to decide these matters that affect us all? I should like to finish, provocatively, with a lengthy quotation from a recent lecture delivered by one of the Justices of the Supreme Court, Lord Sumption.

To sum up, then. We have considered challenging and complex bioethical issues using the Westminster Abbey Institute approach of first, creating a Benedictine space of safety and stability, second, subjecting the matter to rigorous moral analysis and third, coming to a decision, which decisionmaking is the responsibility of the lawmakers and the policymakers. What I have not done is to offer absolute rules or principles which trump every other consideration. It is far better to be morally sensitive than to be morally certain. And so I am agreeing with Lord Sumption that, however fallible it may be, Parliament is the place to fashion legislation on these matters. We do well to attend to whom we put there.

(i) Philip Shepherd, New Self, New World: recovering our senses in the twenty-first century, (Berkeley: North Atlantic Books), 2010 (p 282)(ii) Ronald Dworkin, Taking Rights Seriously, 1977 (Harvard: Harvard University Press)(iii) Sophie Botros and Claire Foster, The moral responsibilities of research ethics committees, in Dispatches, 3:3, Summer 1993(iv) Claire Foster, The Ethics of Medical Research on Humans, (Cambridge: Cambridge University Press) 2001(v)R (on the application of Nicklinson and another) (Appellants) v Ministry of Justice (Respondent); R (on the application of AM) (AP) (Respondent) v The Director of Public Prosecutions (Appellant); R (on the application of AM) (AP) (Respondent) v The Director of Public Prosecutions (Appellant) 25 June 2014(vi) Lord Sumption, The Limits of Law, 27th Sultan Azlan Shah Lecture, Kuala Lumpur, 20 November 2013

Download a transcript of this lecture (PDF, 238KB)

Continue reading here:
The Challenge of Bioethics to Decision-Making in the UK - Westminster Abbey

The 411 on Stem Cells: What They Are and Why It’s Important to Be Educated – Legal Examiner

Medical treatment involving stem cells is an ever-growing, billion-dollar industry, so chances are you have heard about it in the news. Here in the U.S. and around the world, stem cells are being used in various therapies to treat a wide variety of health problems and diseases, including dementia, autism, multiple sclerosis, cerebral palsy, osteoarthritis, cancer, heart disease, Parkinsons disease, and spinal cord injury. Treatments for such health issues may sound promising, but the risk is many of those being sold and advertised arent yet proven to be safe and effective. This is why its so important to educate yourself before jumping into any kind of stem cell treatment.

What are stem cells?

To gain a better understanding of this new age of medical research, one must first understand what stem cells are and how they work. Stem cells are special human cells that can develop into many different types of cells. They can divide and produce more of the same type of stem cells, or they can turn into different functioning cells. There are no other types of cells in the body that have this natural ability to generate new cell types.

Where do stem cells come from?

So where do stem cells that are used for research and medical treatments come from? The three main types of stem cells are embryonic (or pluripotent) stem cells, adult stem cells, and induced pluripotent stem cells.

Embryonic stem cells come from unused, in vitro fertilized embryos that are three to five days old. The embryos are only donated for research purposes with the informed consent of the donors. Embryonic stem cells are pluripotent, which means they can turn into any cell type in the body.

Adult stem cells are found in small numbers in developed tissues in different parts of the body, such as bone marrow, skin, and the brain. They are specific to a certain kind of tissue in the body and are limited to maintaining and repairing the tissue in which they are found. For example, liver stem cells can only make new liver tissue; they arent able to make new muscle tissue.

Induced pluripotent stem cells are another form of adult stem cells. These are stem cells that have been manipulated in a laboratory and reprogrammed to work like embryotic (or pluripotent) stem cells. While these altered adult stem cells dont appear to be clinically different from embryonic stem cells, research is still being conducted to determine if the effects they have on humans differ from actual embryonic stem cells.

Stem cells can also be found in amniotic fluid and umbilical cord blood. These stem cells have the ability to change into specialized cells like embryonic stem cells. While more research is being conducted to determine the potential of these types of stem cells, researchers already actively use these through amniocentesis procedures. In this procedure, the stem cells drawn from amniotic fluid samples of pregnant women can be screened for developmental abnormalities in a fetus.

How stem cells function

The main difference between embryonic and adult stem cells is how they function. Embryonic stem cells are more versatile. Since they can divide into more stem cells or become any type of cell in the body, they can be used to regenerate or repair a variety of diseased tissue and organs. Adult stem cells only generate the types of cells from where they are taken from in the body.

The future of stem cell research

The ability for stem cells to regenerate under the right conditions in the body or in a laboratory is why researchers and doctors have become so interested in studying them. Stem cell research is helping scientists and doctors to better understand how certain diseases occur, how to possibly generate healthy cells to replace diseased cells, and offer ways to test new drugs.

Clearly, stem cell research is showing great potential for understanding and treating a range of diseases and other health issues, but there is still a lot to learn. While there are some diseases that are showing success using stem cell treatments, many others are yet to be proven in clinical trials and should be considered highly experimental.

In our next article, various stem cell treatments, FDA regulations, and other stem cell hot topics will be explored. It will also focus on what to look for when considering stem cell therapies so people arent misled or misinformed about the benefits and risks.

For more information regarding the basics of stem cells visit these sites:

https://stemcells.nih.gov/info/basics/1.htm

https://www.mayoclinic.org/tests-procedures/bone-marrow-transplant/in-depth/stem-cells/art-20048117

Read more:
The 411 on Stem Cells: What They Are and Why It's Important to Be Educated - Legal Examiner

Will Cultured Meat Soon Be A Common Sight In Supermarkets Across The Globe? – Forbes

A hamburger made out of cell-based meat by Mosa Meat, one of many companies throughout the world ... [+] creating beef and other animal products without the animal.

Up until now, plant-based food companies like Beyond Meat, Impossible Foods, and Quorn have almost singlehandedly worked to lessen the impacts of industrial animal agriculture.

Supermarket shelves and fast food restaurants across the US are serving up vegan burgers and meatballs and plant-based chicken nuggets are showing consumers there is an alternative to relying on animal-based protein.

But a quiet revolution is also taking place in labs, where scientists are working to cultivate meat and seafood grown from cells, with the potential to reduce demand for industrial animal agriculture even further.

Heres how the process works: Stem cells are taken from the muscle of an animal, usually with a small biopsy under anesthesia, then theyre put with nutrients, salts, pH buffers, and growth factor and left to multiply. Finessing the technology and getting the cost to an affordable level is happening at a slower pace than the plant-based industry, but a number of start-ups are nevertheless aiming to get their products on the market soon.

Memphis Meats' pan-seared cell-based chicken with sugar snap peas.

Cell-based meat (also known as cultured, cultivated, slaughter-free, cell-cultured, and clean meat) will be a common sight in supermarkets across the west in the next three years, according to theInstitute of the Future in Palo Alto. California-based Memphis Meats made headlines for its world-first cell-based meatballs four years ago, and iscurrently building a pilot plantto produce its cultured beef, chicken, and duck on a bigger scale with plans to launch more plants around the world.

And it isnt the only cell-based meat start-up in the The Golden State. Theres the recently formed San Francisco-basedArtemys Foods, co-founded by biochemist Jess Krieger, who has spent the past six years working at Kent State University in Ohio growing cell-based meat in a lab, Berkeley-basedMission Barns, focusedon creating animal fat, which it has mixed with other ingredients to make duck sausages, and San Diego-based BlueNalu, a startup developing seafood from fish cells through a process called cellular aquaculture.

Close up of BlueNalu's whole-muscle, cell-based yellowtail, beer-battered and deep-fried for fish ... [+] tacos.

But innovation isnt limited to the US its happening across the world.The global cell-based meat market is predicted to be worth$15.5m by 2021 and $20m by 2027,according to analysis.One report estimates that35% of all meat will be cultured by 2040.

While estimates vary, one study found that cell-based beef is projected to use 95 per cent fewer global greenhouse gas emissions, 98 per cent less land use and up to half as much energy. It also significantly reduces the amount of antibiotics needed, which are widely used in agriculture and contribute hugely to worseningantibiotic resistance. And since the animal cells are extracted humanely and grown in a facility rather than within the animals themselves, cell-based meat has the potential to all but eliminate animal suffering.

The industry has made huge progress since the first cell-based hamburger was unveiled in 2013 in London byDutch stem cell researcher Mark Post, chief scientific officer atDutch companyMosa Meat.While this was a huge achievement, it also showed the world how far the industry had to go before commercially viable cell-based meat could be a reality. It cost $325,000 to make, and wasnt totally animal-free, as most of the burgers muscle strands were grown with fetal bovine serum, which comes from blood drawn from bovine fetuses.

In the intervening years, Mosa Meat has made several breakthroughs, and aims to bring the price down to a commercial price. It now doesnt require fetal bovine serum, and hasdeveloped a process thatallows industrial scale production.

Cell-based tartar (raw minced beef, commonly eaten in some of the Northern European countries), ... [+] created by Mosa Meat.

Also in the Netherlands, start-up Meatable has recently raised 9m to help reduce costs and scale-up production of its beef and pork. It aims to havean industry-scale plant by 2025,and will have a small-scale bioreactor the machine where cell-growth takes place - this year.Meatables cofounder Krijn de Nood hopes tounveil its first prototype this summer.

Elsewhere in Europe, the UKs Higher Steaks is growing stem cells for the production of mince for pork sausages. Instead of using fetal bovine serum,the company uses protocols exclusively licensed to itby its collaborators, the University of Minnesota, that allow it to reprogram stem cells into muscle and fat tissues.

Instead of adult stem cells, it uses induced pluripotent stem cells, which means they have an infinite supply as the cells proliferate infinitely. With adult stem cells, researchers have to go to the animal every time they need a new batch.

AndSpains Cubiq Foodsis producing cell-based fat, which is used to enhance the flavor of food and enrich it with essential fatty acids, such as omega-3.

But when it comes to cell-based meat, all eyes are on Israel, where a number of start-ups likeFuture Meat Technologies and SuperMeat are making huge progress. The countrys interest in cell-based meat has also been attributed to its thriving vegan culture.

Comparison of Future Meat Technologies' cell-based chicken (left) to of farm-raised chicken (right). ... [+]

Future Meat Technologies, founded in 2018, has shortened the manufacturing process to two weeks, with a patent-pending method they say allows for higher production yields of cell-based beef. The start-up's technologies enable producers, farmers and retailers to manufacture biomass and process it locally. The company hopes toget cost down to $10 per poundby 2022.

As for SuperMeat, it is developing cell-based meat from chicken cells (it claimed during its launch in 2016 that it wasthe first company to work on clean chicken productsfor mass production). One of Europe's largest poultry producers,PHW-Gruppe formed a partnershipwith SuperMeat in 2018. We believe 2020 will be the tipping point for the cultivated meat industry, once the proof of scale will be introduced to the world, says Shir Friedman, Co-Founder and Chief Communications Officer of the company. SuperMeat is excited to take a lead part in this historical event."

An illustration of SuperMeat's cell-based meat cultivators of the future.

Another Israeli start-up,Aleph Farms, created the worlds first cell-based steak at the end of 2018.It was co-founded only one year prior together with The Kitchen Hub from the Strauss Group, and with Professor Shulamit Levenberg of the Technion Institute of Technology. And in fall of 2019,Aleph Farmssuccessfully3D printedmeat on the International Space Station. Our experiment ofbioprintingmeat in space... consisted of printing a small-scale muscle tissue using 3D Bioprinting Solutions bioprinting technology, says Yoav Reisler, External Relations Manager for the company. The proof of concept sought to assess the potential of producing cultivated meat in a zero-gravity environment away from land and local water resources. Our approach for cultivating beef steaks is imperative to the experiment, as it relies on mirroring the natural process of tissue regeneration that happens in a cows body but under controlled and animal-free conditions. Our overarching goal is to produce meat products that have a significantly reduced ecological impact and this was a milestone in towards achieving that. Earlier this month, Aleph Farms announced plans to open an educational complex next to its production facility to provide the general public a more in-depth view of how cell-based meat is grown.

Thin-cut beef steaks cultivated by Aleph Farms.

Also in Israel,BioFood Systemsaims to produce beef products using bovine embryonic stem cells. It also hopes to scale up technology that it can license globally toenable meatmanufacturers to produce their own cell-based meat.

But other parts of the world arent far behind Israel, including Asia. Singaporean Shiok Meats is working on bringing cell-based based crustaceans (shrimp, crab and lobster) to market, and says its the first company of its kind in Singapore and South-East Asia. It hopes to have a commercially viable product in the next few years, and is currently researching and developing.

Shiok Meats cell-grown shrimp dumplings.

And in Japan, meat producer Toriyama and its export agent, Awano Food Group has partnered with JUST to grow, distribute and sell its cell-based wagyu beef worldwide.

JUST doesn't yet have images of its cell-based wagyu because its still in early stage R&D, but it ... [+] may one day look like this animal-based piece of Wagyu beef steak seen here.

In-between Asia and Europe, innovation is also happing in Turkey. Biftek is the first and still the only companydeveloping cultured meat in the country. It uses a plant-based formulation, made up of 44 proteins, in place of fetal bovine serum. Founder Can Akcali said in a recent interview that the media in Turkey is showing a growing interest in its work, and cell-based meat more widely.

Since the first cell-based unveiling of a cell-based burger in 2013, scientists have been flocking to labs in a race to iron out numerous teething problems and be the first to make a commercially viable cell-based meat product. Meanwhile, private investment into the industry has soared. Last year, twelve companiesraised $50 million in 14 deals double the amount of 2018. US-based Memphis Meats raised $22 million, Spain's Cubiq Foods raised $14 million and Mosa Meat drew in $9 million.

Memphis Meats now plans to build a pilot production facility,thanks to additional investments in January this yearfrom Cargill and Tyson Foods, as well as high-profile investors Bill Gates, Richard Branson, and Kimbal Musk.

Ido Savir, SuperMeats chief executive, said Mosa Meat introduced the concept of cell-based meat to the world, and that the main challenge start-ups are still facing is proof of scaling up production to a commercially viable size that's cost-efficient. Once these hurdles are overcome, it will be a much smoother process to get cell-based meat on shelves. At the moment, cell-based products are being prototyped in labs - but once scientists have finessed the process and the cost, theyre produced at scale and can grow in facilities like any other food.

Many cell-based start-ups expect to get their products to market in the next few years. Whether or not they are actually able to meet that projection is an open question. I worry most startups in the cultured meat space are overestimating their short-term timeline to get to market and underestimating their potential long-term impact on completely redesigning our food system from the cell-level up, says Max Elder, Research Director in the Food Futures Lab at Institute for the Future. Regardless of the timeline, one thing is clear: we desperately need to undo the damage industrialized animal agriculture is wreaking on our communities, animal, and planet. While it may indeed be unwise to count our cultured chickens before they hatch, especially in light of the urgent challenges we are facing, we can no doubt expect more innovation in the coming years. Perhaps one day - even if not in the near future - all the meat on our plates will indeed be slaughter-free.

Read this article:
Will Cultured Meat Soon Be A Common Sight In Supermarkets Across The Globe? - Forbes

Genetic Secrets of How a Strange Marine Animal Produces Unlimited Eggs and Sperm Over Its Lifetime – SciTechDaily

Piwi1-positive spermatogonia are shown in yellow; cell nuclei are in turquoise. Germ cell induction and all stages of gametogenesis can be visualized in these clonal animals. Credit: Timothy DuBuc, Ph.D. Swarthmore College

National Human Genome Research Institute-supported research of Hydractinia could provide clues to human reproductive conditions.

A little-known ocean-dwelling creature most commonly found growing on dead hermit crab shells may sound like an unlikely study subject for researchers, but this animal has a rare ability it can make eggs and sperm for the duration of its lifetime. This animal, called Hydractinia, does so because it produces germ cells, which are precursors to eggs and sperm, nonstop throughout its life. Studying this unique ability could provide insight into the development of human reproductive system and the formation of reproductive-based conditions and diseases in humans.

By sequencing and studying the genomes of simpler organisms that are easier to manipulate in the lab, we have been able to tease out important insights regarding the biology underlying germ cell fate determination knowledge that may ultimately help us better understand the processes underlying reproductive disorders in humans, Dr. Andy Baxevanis, director of the National Human Genome Research Institutes (NHGRI) Computational Genomics Unit and co-author of the paper. NHGRI is part of the National Institutes of Health.

Piwi1-positive oocytes are shown in yellow; cell nuclei are in turquoise. Germ cell induction and all stages of gametogenesis can be visualized in these clonal animals. Credit: Timothy DuBuc, Ph.D. Swarthmore College

In a study published in the journal Science, collaborators at NHGRI, the National University of Ireland, Galway, and the Whitney Laboratory for Marine Bioscience at the University of Florida, Augustine, reported that activation of the gene Tfap2 in adult stem cells in Hydractinia can turn those cells into germ cells in a cycle that can repeat endlessly.

In comparison, humans and most other mammals generate a specific number of germ cells only once in their lifetime. Therefore, for such species, eggs and sperm from the predetermined number of germ cells may be formed over a long period of time, but their amount is restricted. An international team of researchers have been studying Hydractinias genome to understand how it comes by this special reproductive ability.

Hydractinia lives in colonies and is closely related to jellyfish and corals. Although Hydractinia is dissimilar to humans physiologically, its genome contains a surprisingly large number of genes that are like human disease genes, making it a useful animal model for studying questions related to human biology and health.

Hydractinia colonies possess feeding polyps and sexual polyps as a part of their anatomy. The specialized sexual polyps produce eggs and sperm, making them functionally similar to gonads in species like humans.

Timing of germ cell formation in Hydractinia versus most animals. Credit: Timothy DuBuc, Ph.D. Swarthmore College

During human embryonic development, a small pool of germ cells that will eventually become gametes is set aside, and all sperm or eggs that humans produce during their lives are the descendants of those original few germ cells. Loss of these germ cells for any reason results in sterility, as humans do not have the ability to replenish their original pool of germ cells.

In a separate study, Dr. Baxevanis at NHGRI and Dr. Christine Schnitzler at the Whitney Lab have completed the first-ever sequencing of the Hydractinia genome. In this study, researchers used this information to scrutinize the organisms genome for clues as to why there are such marked differences in reproductive capacity between one of our most distant animal relatives and ourselves.

Having this kind of high-quality, whole-genome sequence data in hand allowed us to quickly narrow down the search for the specific gene or genes that tell Hydractinias stem cells to become germ cells, said Dr. Baxevanis.

The researchers compared the behavior of genes in the feeding and sexual structures of Hydractinia. They found that the Tfap2 gene was much more active in the sexual polyps than in the feeding polyps in both males and females. This was a clue that the gene might be important in generating germ cells.

The scientists next confirmed that Tfap2 was indeed the switch that controls the process of perpetual germ cell production. The researchers used the CRISPR-Cas9 gene-editing technique to remove Tfap2 from Hydractinia and measured the resulting effects on germ cell production. They found that removing Tfap2 from Hydractinia stops germ cells from forming, bolstering the theory that Tfap2 controls the process.

The researchers also wanted to know if Tfap2 was influencing specific cells to turn into germ cells. Their analysis revealed that Tfap2 only causes adult stem cells in Hydractinia to turn into germ cells.

Interestingly, the Tfap2 gene also regulates germ cell production in humans, in addition to its involvement in myriad other processes. However, in humans, the germ cells are separated from non-germ cells early in development. Still, despite the vast evolutionary distance between Hydractinia and humans, both share a key gene that changes stem cells into germ cells.

Reference: Transcription factor AP2 controls cnidarian germ cell induction by Timothy Q. DuBuc, Christine E. Schnitzler, Eleni Chrysostomou, Emma T. McMahon, Febrimarsa, James M. Gahan, Tara Buggie, Sebastian G. Gornik, Shirley Hanley, Sofia N. Barreira, Paul Gonzalez, Andreas D. Baxevanis and Uri Frank, 14 February 2020, Science.DOI: 10.1126/science.aay6782

This article describes a basic research finding. Basic research increases our understanding of human behavior and biology, which is foundational to advancing new and better ways to prevent, diagnose and treat disease. Science is an unpredictable and incremental process each research advance builds on past discoveries, often in unexpected ways. Most clinical advances would not be possible without the knowledge of fundamental basic research.

The National Human Genome Research Institute (NHGRI) is one of the 27 institutes and centers at the NIH, an agency of the Department of Health and Human Services. The NHGRI Division of Intramural Research develops and implements technology to understand, diagnose and treat genomic and genetic diseases.

Original post:
Genetic Secrets of How a Strange Marine Animal Produces Unlimited Eggs and Sperm Over Its Lifetime - SciTechDaily

Stem Cells Market Report by Manufacturers, Regions, Type and Application Forecast 2020-2025, Trends, Proportions, Share and SWOT. – Chronicle 99

The Report titled: Global Stem Cells Market Analysis: Production, Capacity, Sales, Revenue, Trends, Revenue Share, and Forecast till 2025

The authors of the Stem Cells Market Report have done extensive study of the global Stem Cells market keeping in mind the key aspects such as growth determinants, opportunities, challenges, restraints, and market developments. This analysis will enrich the ability of the companies involved in the global Stem Cells market to make precise decisions. The report also emphasizes on the current and future trends in the global Stem Cells market, which may bode well for the global Stem Cells market in the coming years.

The Stem cells are the cells found in the umbilical cord blood. These cells are being used in treating a wide range of conditions like sickle cell disease, leukaemia, and multiple myeloma. Birth of the child is the only chance to collect and store these valuable stem cells, which can be used to treat over 80 diseases. The Global Stem Cells Market was 5.21 Billion USD in 2018 and is estimated to reach 9.55Billion USD by 2025 at a CAGR of 9.04% during the forecast period

Get Free Exclusive Sample of this Premium Report at @ https://www.esherpamarketreports.com/request-sample/es-14599/

Table of Contents:1. Research Methodology2. Executive Summary3. Market Overview3.1. Definition3.2. Industry Value Chain Analysis3.3. Porters 5 Forces3.4. Regulations4. Market Dynamics4.1. Introduction4.2. Drivers4.3. Constraints4.4. Trends5. Global Stem Cells Market Segmentation, Forecasts and Trends by Product Type5.1. Adult Stem Cells5.2. Human Embryonic Stem Cells5.3. Induced Pluripotent Stem Cells5.4. Others6. Global Stem Cells Market Segmentation, Forecasts and Trends by Source6.1. Autologous6.2. Allogeneic7. Global Stem Cells Market Segmentation, Forecasts and Trends by Application7.1. Regenerative Medicine7.2. Drug Discovery & Development

Click Here For Detailed Table Of Contents

Enquire before purchasing this report @ https://www.esherpamarketreports.com/pre-order-enquiry/es-14599

Key Highlights of Stem Cells Market Report:

Reasons To Buy:

Purchase this Report with Full Access @ https://www.esherpamarketreports.com/purchase/es-14599/

Contact Us:

Name: Jason George

Email: sales@esherpamarketreports.com

Call :USA: +1 408 757 0510

Organization: eSherpa Market Reports

About Us:

eSherpa Market Reports is a credible source for gaining the market research reports that will exponentially accelerate your business. We are among the leading report resellers in the business world committed to optimizing your business. The reports we provide are based on research that covers a magnitude of factors such as technological evolution, economic shifts and a detailed study of market segments.

Read this article:
Stem Cells Market Report by Manufacturers, Regions, Type and Application Forecast 2020-2025, Trends, Proportions, Share and SWOT. - Chronicle 99

Embryonic Stem Cells

By: Ian Murnaghan BSc (hons), MSc - Updated: 8 Feb 2019| *Discuss

Embryonic stem cells have generated an enormous amount of ethical controversy and discussion, primarily because of their source. As the name implies, embryonic stem cells are derived from embryos. As with all stem cells, embryonic stem cells are unspecialised cells that have the ability to:

The embryonic stem cells are usually derived from in vitro fertilisation, where the eggs have been fertilised in vitro (not in a woman's body) and donated for research with donor consent. The embryos are generally utilised when they are approximately four or five days old and constitute a tiny ball of cells known as a blastocyst. Pluripotent embryonic stem cells are derived from the blastocyst. Embryonic stem cells can, however, be either totipotent or pluripotent cells. Those cells that are totipotent include the fertilised egg itself as well as the cells produced during the very early divisions. These totipotent embryonic stem cells have the ability to become any cell in the human body. Pluripotent stem cells, on the other hand, can become any type of cell in the body except those needed to develop a foetus.

Research on embryonic stem cells can also improve the safety of drugs. By testing drugs on embryonic stem cell lines, scientists can gauge their safety before testing them further in laboratory animals and human subjects. Also beneficial would be the knowledge of precisely how embryonic stem cells differentiate and proliferate. Many serious medical conditions such as cancer and birth defects result from dysfunctional cell replication and specialisation. If researchers can learn exactly what happens during normal healthy cell development, they can better understand what happens to lead to disease.

Embryonic stem cells are certainly a promising discovery, but their use will likely not become consistent and approved until procedures for isolating and growing them are proven and defined. A lack of widespread public acceptance also clouds the therapeutic use of embryonic stem cells but hopefully, the concerns and challenges can be overcome in the future so that those suffering from serious diseases can benefit from embryonic stem cells.

You might also like...

Share Your Story, Join the Discussion or Seek Advice..

Sarah - 5-Nov-15 @ 1:20 AM

Hope - 20-May-15 @ 12:22 AM

tezza - 22-May-12 @ 10:43 AM

Title:

(never shown)

Originally posted here:
Embryonic Stem Cells

3. Embryonic Stem Cells | Stem Cells and the Future of …

PROPERTIES OF ESCs IMPORTANT FOR REGENERATIVE MEDICINE

Human ESCs were successfully grown in the laboratory for the first time in 1998 (Thompson et al., 1998). Under appropriate culture conditions, ESCs have demonstrated a remarkable ability to self-renew continuously, that is, to produce more cells like themselves that are multipotent. As indicated at the workshop by Thomas Okarma and Ron McKay, ESC lines established from single cells have been demonstrated to proliferate through 300-400 population-doubling cycles. Human ESCs that have been propagated for more than 2 years also demonstrate a stable and normal complement of chromosomes, in contrast to the unstable and abnormal complement of embryonic cancer cell lines used in the past to study early stages of embryonic development. Careful monitoring of the aging ESC lines will be needed to evaluate the significance of genetic changes that are expected to occur over time.

Because human ESCs have only recently become available for research, most of what is known about ESCs comes from studies in the mouse, which, as noted in Chapter 2, cannot be presumed to provide definitive evidence of the capabilities of human cells.

Nevertheless, ESCs derived from mouse blastocysts have been studied for 2 decades and provide a critical baseline of knowledge about the biology and cultivation of these cells (Torres, 1998; Wobus and Boheler, 1999). The factors that permit the mouse ESC to continue replicating in the laboratory without differentiation and methods to trigger differentiation into different cell types that exhibit normal function have been actively explored. Among the types of cells derived from cultured mouse ESCs are fat cells, various brain and nervous system cells, insulin-producing cells of the pancreas, bone cells, hematopoietic cells, yolk sac, endothelial cells, primitive endodermal cells, and smooth and striated muscle cells, including cardiomyocytesheart muscle cells (Odorico et al., 2001).

Experience with mouse ESCs has provided clues to methods for culturing human ESCs and leading them to differentiate. Mouse ESCs

Continued here:
3. Embryonic Stem Cells | Stem Cells and the Future of ...

Embryonic Stem Cell Fact Sheet

What are embryonic stem cells? All embryonic stem cells are undifferentiated cells that are unlike any specific adult cell. However, they have the ability to form any adult cell. Because undifferentiated embryonic stem cells can proliferate indefinitely in culture, they could potentially provide an unlimited source of specific, clinically important adult cells such as bone, muscle, liver or blood cells.

Where do embryonic stem cells come from? Human embryonic stem cells are derived from in vitro fertilized embryos less than a week old. These embryos were produced for clinical purposes, but were no longer wanted for implantation by the couples who donated them. They were donated specially for this project with the informed consent of donors. In virtually every in vitro fertilization clinic in the world, surplus embryos are discarded if they are not donated to help other infertile couples or for research. The research protocols were reviewed and approved by a UWMadison Institutional Review Board, a panel of scientists and medical ethicists who oversee such work.

Why are they important? Embryonic stem cells are of great interest to medicine and science because of their ability to develop into virtually any other cell made by the human body. In theory, if stem cells can be grown and their development directed in culture, it would be possible to grow cells of medical importance such as bone marrow, neural tissue or muscle.

What, precisely, has the UW team accomplished? Scientists have been attempting to isolate and culture human embryonic stem cells for more than a decade. Using 14 blastocysts obtained from donated, surplus embryos produced by in vitro fertilization, the Wisconsin group established five independent cell lines. The cell lines, derived from preimplantation stage embryos, were capable of prolonged, undifferentiated proliferation in culture and yet maintained the ability to develop into a variety of specific cell types, including neural, gut, muscle, bone and cartilage cells.

How might they be used to treat disease? The ability to grow human tissue of all kinds opens the door to treating a range of cell-based diseases and to growing medically important tissues that can be used for transplantation purposes. For example, diseases like juvenile onset diabetes mellitus and Parkinsons disease occur because of defects in one of just a few cells types. Replacing faulty cells with healthy ones offers hope of lifelong treatment. Similarly, failing hearts and other organs, in theory, could be shored up by injecting healthy cells to replace damaged or diseased cells.

Are there other potential uses for these cells? The first potential applications of human embryonic stem cell technology may be in the area of drug discovery. The ability to grow pure populations of specific cell types offers a proving ground for chemical compounds that may have medical importance. Treating specific cell types with chemicals and measuring their response offers a short-cut to sort out chemicals that can be used to treat the diseases that involve those specific cell types. Ramped up stem cell technology would permit the rapid screening of hundreds of thousands of chemicals that must now be tested through much more time-consuming processes.

What can these cells tell us about development? The earliest stages of human development have been difficult or impossible to study. Human embryonic stem cells will offer insights into developmental events that cannot be studied directly in humans in utero or fully understood through the use of animal models. Understanding the events that occur at the first stages of development has potential clinical significance for preventing or treating birth defects, infertility and pregnancy loss. A thorough knowledge of normal development could ultimately allow the prevention or treatment of abnormal human development. For instance, screening drugs by testing them on cultured human embryonic stem cells could help reduce the risk of drug-related birth defects.

If a cluster of these cells was transferred to a woman, could a pregnancy result? No. These cells are not the equivalent of an intact embryo. If a cluster of these cells was transferred to a uterus, they would fail to implant, and would fail to develop into a fetus.

Is stem cell research the same as cloning?No. Stem cell research aims to develop new life-saving treatments, and cannot be used to develop a human being. Embryonic stem cells derived from the inner cell mass of an early-stage embryo cannot give rise to a placenta, so a human being could not develop, even if the stem cells were implanted into a womans uterus.

Why not derive stem cells from adults?There are several approaches now in human clinical trials that utilize mature stem cells (such as blood-forming cells, neuron-forming cells and cartilage-forming cells). However, because adult cells are already specialized, their potential to regenerate damaged tissue is very limited: skin cells will only become skin and cartilage cells will only become cartilage. Adults do not have stem cells in many vital organs, so when those tissues are damaged, scar tissue develops. Only embryonic stem cells, which have the capacity to become any kind of human tissue, have the potential to repair vital organs.

Studies of adult stem cells are important and will provide valuable insights into the use of stem cell in transplantation procedures. However, only through exploration of all types of stem cell research will scientists find the most efficient and effective ways to treat diseases.

What are the benefits of studying stem cells?Pluripotent stem cells represent hope for millions of Americans. They have the potential to treat or cure a myriad of diseases, including Parkinsons, Alzheimers, diabetes, heart disease, stroke, spinal cord injuries and burns.

This extraordinary research is still in its infancy and practical application will only be possible with additional study. Scientists need to understand what leads cells to specialization in order to direct cells to become particular types of tissue. For example, islet cells control insulin production in the pancreas, which is disrupted in people with diabetes. If an individual with diabetes is to be cured, the stem cells used for treatment must develop into new insulin-producing islet cells, not heart tissue or other cells. Research is required to determine how to control the differentiation of stem cells so they will be therapeutically effective. Research is also necessary to study the potential of immune rejection of the Cells, and how to overcome that problem.

Share via Facebook

Share via Twitter

Share via Linked In

Share via Email

More here:
Embryonic Stem Cell Fact Sheet